吸入药物用于小儿非囊性纤维化支气管切除症的维持疗法
Emily M Harvath Gray1, Rebecca S Pettit1, Samantha Engdahl1
1Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, IN, USA.
The Annals of pharmacotherapy
|September 19, 2024
概括
吸入疗法,如高血压盐水和抗生素,对儿科非囊性纤维化支气管炎有希望. 然而,需要进行更多的研究,以为这些具有挑战性的病例制定明确的治疗指南.
科学领域:
- 肺部病理学 肺部病理学
- 儿科呼吸系统医学 儿科呼吸系统医学
背景情况:
- 儿童非囊性纤维化支气管切除症 (NCFB) 存在重大管理挑战.
- 对于儿科NCFB的最佳吸入维持疗法的证据有限.
研究的目的:
- 对儿童NCFB吸入性粘结剂,抗生素和皮质类固醇的文献进行审查和评估.
- 评估这些吸入剂对NCFB管理的风险和益处.
主要方法:
- 进行了全面的PubMed文献搜索.
- 关键词包括"非囊性纤维化支气管病变","初级状腺功能障碍",以及与吸入剂结合的"支气管病变".
- 包括从1998年到2024年7月发表的专注于儿科NCFB的研究.
主要成果:
- 高血压盐水可能有助于低风险的气道清除.
- 吸入的抗伪体抗生素被推用于Pseudomonas aeruginosa的殖民.
- 吸入性皮质类固醇最好保留给同时患有喘的患者.
结论:
- 吸入的抗假体抗生素和高血压盐水对儿科NCFB有更强的证据依据.
- 由于潜在的负面结果,dornase alfa的使用需要谨慎使用.
- 为了确定吸入疗法在儿科NCFB中的作用,进一步的研究是必不可少的.
相关概念视频
Inhaled Medications
240
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
240
Drugs Used in Lower Respiratory Disorders: Overview
360
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
360
Cystic Fibrosis: Management
145
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
145
COPD: Management Using Bronchodilators and Corticosteroids
186
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
186
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K


